Waiting
Traitement de la connexion…

Trial ends in Request Full Access Tell Your Colleague About Jove
Journal / Medicine / Ex Vivo Treatment Response of Primary Tumors…
JoVE Journal
Medicine

Un abonnement à JoVE est nécessaire pour afficher ce contenu. Connectez-vous ou commencez votre essai gratuit.

JoVE Journal Medicine
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
 

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Article DOI: 10.3791/52157-v • 08:29 min • October 2nd, 2014
October 2nd, 2014 •
*1, *2, 3, 4, 5, 5, 2, 6
1Department of Pathology, Memorial Sloan Kettering Cancer Center, 2Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 3Department of Radiology, Weill Cornell Medical College, 4Department of Medicine, Memorial Sloan Kettering Cancer Center, 5Department of Oncology, Memorial Sloan Kettering Cancer Center, 6Department of Surgery, Memorial Sloan Kettering Cancer Center
* These authors contributed equally

Chapitres

résumé
Automatic Translation

Established cancer cell lines and xenografts have been the mainstay of cancer research for the past several decades. However, recent evidence suggests that therapeutic response is greatly influenced by the tumor cell microenvironment. Therefore, we have developed an ex vivo analysis of primary tumor specimens for drug development purposes.

Tags

Ex Vivo Tumor Model Primary Tumor Samples Tumor Microenvironment Treatment Response Preclinical Drug Development Clinical Therapeutics Cancer Cell Lines Tumor Xenografts Tumor-microenvironment Crosstalk Tissue Sectioning
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter